Recording two-digit growth since its inception, Horus Pharma ended the year 2023 with a turnover of €93 million, up 10% on the previous year.
Horus Pharma is now a leading key player on its markets and continues its dynamic European expansion. Its headquarters are located in France in the Alpes-Maritimes. The company distributes its products in France, and internationally through its subsidiaries in Belgium, the Netherlands, Luxembourg, Spain, Switzerland, and Scandinavia, as well as in many other countries through distribution agreements.
With a sustained recruitment policy of 10% annual hiring, Horus Pharma has established itself as a thriving SME and employment generator in the Nice area.
Innovation takes the form of a sustained rate of product launches, patent filing and expansion of the product portfolio, referencing more than 50 products covering all therapeutic segments in ophthalmology.
Since the creation of the Laboratory, gender equality has always been favoured and over 70% of the company's staff are women, 40% of whom are in the Management Committee, including the President and founder.
Horus Pharma is now a leading key player on its markets and continues its dynamic European expansion. The company distributes its products in France, and internationally through its subsidiaries in Belgium, the Netherlands, Luxembourg, Spain, Switzerland, and Scandinavia, as well as in many other countries through distribution agreements.